Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.
about
A review of the evidence to support influenza vaccine introduction in countries and areas of WHO's Western Pacific RegionSafety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines.Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Sociodemographic factors and clinical conditions associated to hospitalization in influenza A (H1N1) 2009 virus infected patients in Spain, 2009-2010.Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or olderImmune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.From discovery to licensure, the Adjuvant System story.Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan.A(H1N1)pdm09 vaccination of health care workers: improved immune responses in low responders following revaccination.
P2860
Q30352256-0A427867-6A0A-42EB-95C6-9A5BD17F84BCQ30369467-13822247-9E0B-42E4-9EFE-D21EAED7936AQ30401398-EC23C246-1939-4730-AC0D-286B748B231FQ30407050-6B747A78-2AA6-4DE6-A351-EC2D02DE9433Q30407911-64BD36BB-8747-4351-8F8D-5A33FF540E72Q30413695-6C77C4A2-F202-4283-9B21-62EFA8D2CD64Q30414225-33EE0983-14C9-4DA0-8812-95C1CBABB5F6Q30414384-CB67FE8E-276B-4376-871C-9617B5E4793EQ30415263-DAD51266-F022-48A3-AAA7-D6B1302C27BEQ30419943-9FCF5401-5FBE-4699-8385-216C28482B14Q30420476-9E72CD68-5211-4F34-AE74-F13FFF745C7DQ30429185-2A9D312C-FB9B-41F0-B005-23B8D23E3BF4Q37619140-3B94C6D1-EED7-497F-AC69-C1D6F0C2F221Q43171863-D34F8052-D8AB-4873-93AB-13364E072DE7Q50938543-CCC84A5D-F94C-4413-8F7C-896F47E2C82C
P2860
Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Immunogenicity and safety of a ...... za vaccine in adults in Japan.
@ast
Immunogenicity and safety of a ...... za vaccine in adults in Japan.
@en
type
label
Immunogenicity and safety of a ...... za vaccine in adults in Japan.
@ast
Immunogenicity and safety of a ...... za vaccine in adults in Japan.
@en
prefLabel
Immunogenicity and safety of a ...... za vaccine in adults in Japan.
@ast
Immunogenicity and safety of a ...... za vaccine in adults in Japan.
@en
P2093
P356
P1433
P1476
Immunogenicity and safety of a ...... za vaccine in adults in Japan.
@en
P2093
Atsushi Maeda
François Roman
Hideaki Nagai
Hideyuki Ikematsu
Kazuyoshi Tenjinbaru
Masahiro Kawashima
Paul Gillard
Yasunobu Kawakami
P304
P356
10.4161/HV.6.11.12851
P577
2010-11-01T00:00:00Z